Breakthrough Cancer Pain, Quality of Life
Conditions
Keywords
Breakthrough cancer pain, diary, quality of life, Abstral, BTcP
Brief summary
This Observational Registry study is designed to collect self-reported Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access program-enrolled patient experience with breakthrough cancer pain (BTcP) as a result of treatment with Abstral® through the use of Quality of Life and pain measurement tools administered via questionnaire.
Detailed description
This is a post-marketing, single arm, open label multicenter trial to assess Abstral (fentanyl) Sublingual Tablets for breakthrough cancer pain (BTcP) in opioid-tolerant cancer patients. * Prior to study enrollment, patient enrollment in the TIRF REMS Access program must be confirmed. * Eligible patients will sign written informed consent. Patients or their proxy with a witness must be able to sign written informed consent to participate in the study; and the patient may use a proxy caregiver to assist in the completion of the study questionnaires. * Day 0, study site must enroll patient by completing a patient demographic profile (de-identified). * Day 0, patient will be instructed how to use the questionnaires. * Day 0, patient will complete the baseline questionnaire before leaving the physician office. * On study Days 14, 21, and 28 (±3 days) patient questionnaire will be completed by patient (or caregiver proxy) via secure online data entry portal. * For patients completing paper questionnaires, within 1 month of day 28, patient will return completed questionnaires via mail, fax or hand carried to the study site coordinator for processing. * Patient will be considered to have completed the study successfully once all completed questionnaires have been received by the CRO within appropriate time limits.
Interventions
DRUGFentanyl
Sponsors
Galena Biopharma, Inc.
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All patients 18 years of age and older with breakthrough cancer pain who are registered in the Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access program and receiving Abstral® under the direction of a TIRF REMS Access program-registered physician are eligible for the study. Patients or their proxy with a witness must be able to sign written informed consent to participate in the study; and the patient may also use a proxy caregiver to assist in the completion of the study questionnaires.
Exclusion criteria
* No patient can be enrolled who has not been prescribed Abstral for BTcP in compliance with Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access program guidelines. No patient may be enrolled who has a contraindication to receiving Abstral or who is pregnant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life | One month | Primary: To compare self reported TIRF REMS Access-enrolled patient experience with BTcP at baseline (before using Abstral) to their experience after reaching a maintenance dose of Abstral * Characterize the effectiveness of treatment with Abstral in select pain and quality-of-life (QoL) domains * Abstral impact on pain interference with daily activities, somnolence, and oral health |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rapidity of BTcP | one month | Trends in improvement or deterioration in these values during treatment and across the dosage groups will be described. |
Countries
United States
Outcome results
None listed